Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 26, 2011
EISAI RESUBMITS AMPA RECEPTOR ANTAGONIST PERAMPANEL (E2007) NDA TO U.S. FDA
December 21, 2011
EISAI SUBMITS APPLICATION FOR PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NEUZYM®
December 15, 2011
EISAI ANNOUNCES CANADIAN APPROVAL OF ITS ANTICANCER AGENT HALAVEN™
December 13, 2011
EISAI SUBMITS APPLICATION IN JAPAN FOR NEW DRY SYRUP FORMULATION OF ITS ALZHEIMER'S DISEASE TREATMENT ARICEPT®
December 2, 2011
EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT
Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics
December 1, 2011
EISAI'S CANADIAN SALES SUBSIDIARY CELEBRATES OFFICIAL INTRODUCTION TO CANADA
November 30, 2011
EISAI ANNOUNCES JAPAN LAUNCH OF ORAL ANTICOAGULANT WARFARIN GRANULES 0.2%
November 18, 2011
EISAI ENTERS INTO JAPAN CO-PROMOTION AGREEMENT WITH NOVARTIS PHARMA FOR COPD THERAPIES
October 31, 2011
EISAI SUPPORTS RELIEF EFFORTS FOR THAILAND FLOOD VICTIMS
To Make US$100,000 Donation to Thailand Red Cross Society
October 26, 2011
EISAI JOINS WIPO SPONSORED GLOBAL CONSORTIUM FOR NEGLECTED TROPICAL DISEASE RESEARCH AND DEVELOPMENT
October 17, 2011
EISAI ENTERS INTO NEUROLOGICAL DRUG DISCOVERY RESEARCH COLLABORATION WITH JOHNS HOPKINS UNIVERSITY
September 28, 2011
Abbott Japan and Eisai Announce Launch of Humira® Prefilled Syringe 20mg/0.4mL, a New Formulation for the Treatment of Juvenile Idiopathic Arthritis in Patients with Low Body Weight
September 26, 2011
Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira® (adalimumab), a Fully Human Anti-TNF-伪 Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis
September 14, 2011
SUPREME COURT OF JAPAN RULES TO EXTEND EISAI'S PATENT FOR ARICEPT® IN RELATION TO SEVERE ALZHEIMER'S DISEASE
September 7, 2011
EISAI TO ACCELERATE LATE-STAGE CLINICAL DEVELOPMENT OF NEW DRUGS BY EFFECTIVELY LEVERAGING EXTERNAL RESOURCES
Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib)
September 6, 2011
EISAI TO LAUNCH NEW SELBELLE® TABLETS AND NEW SELBELLE® FINE GRANULES
New Medications to Alleviate Post Meal Stomach Heaviness
September 2, 2011
EISAI DISCONTINUES DEVELOPMENT OF PARIET®/ACIPHEX® EXTENDED-RELEASE CAPSULES, 50 MG
September 1, 2011
EISAI PRESENTS NEW RESEARCH ON EPILEPSY PIPELINE, PORTFOLIO AT THE 29TH INTERNATIONAL EPILEPSY CONGRESS
Looks to Expand Global Epilepsy Product Portfolio
August 31, 2011
Toyama Chemical and Eisai Submit Marketing Authorization Application for Anti-Rheumatic Agent T-614
August 29, 2011
Abbott Japan and Eisai Announce Launch of Pancreatic Digestive Enzyme Replacement Drug Lipacreon® (pancrelipase)
August 17, 2011
EISAI ESTABLISHES SALES SUBSIDIARY IN MEXICO
August 10, 2011
PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography Receives Approval in Japan
August 2, 2011
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)
July 29, 2011
U.S. FDA PROVIDES RESPONSE TO PERAMPANEL NEW DRUG APPLICATION
July 28, 2011
EMA ACCEPTS EISAI'S LICENSE EXTENSION APPLICATION FOR ANTIEPILEPTIC AGENT ZONEGRAN® AS A MONOTHERAPY
July 19, 2011
EISAI ANNOUNCES JAPAN LAUNCH OF ANTICANCER AGENT HALAVEN®
July 14, 2011
EISAI ANNOUNCES FDA ACCEPTANCE OF sNDA SUBMISSION FOR DACOGEN® IN ACUTE MYELOID LEUKEMIA
July 13, 2011
EISAI ENTERS INTO COMPREHENSIVE CHINESE MARKETING AGREEMENT CONCERNING BREAST CANCER AND PARKINSON'S DISEASE TREATMENTS
July 7, 2011
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
July 1, 2011
Abbott Japan and Eisai Receive Approval in Japan for Additional Indication and New Formulation of Humira®, a Fully Human Anti-TNF-α Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis
June 28, 2011
EISAI'S ANTIEPILEPTIC AGENT BANZEL™ RECEIVES APPROVAL IN CANADA
June 24, 2011
EUROPEAN MEDICINES AGENCY ACCEPTS FOR REVIEW EISAI'S MAA FOR AMPA RECEPTOR ANTAGONIST PERAMPANEL (E2007)
June 21, 2011
Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 10, 2011
Information Regarding Voluntary Recall of Chocola® BB Sparkling (Vitamin Drink) Due to Mislabeling of Nutritional Information
June 7, 2011
PHASE Ⅲ STUDY OF DNA METHYLATION INHIBITOR DACOGEN® FOR INJECTION IN ACUTE MYELOID LEUKEMIA PRESENTED AT ASCO
June 2, 2011
PHASE Ⅱ STUDY RESULTS SHOWED EISAI'S LENVATINIB (E7080) DEMONSTRATED AN OBJECTIVE RESPONSE RATE OF 59% IN ADVANCED RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
May 25, 2011
EISAI-UNIVERSITY COLLEGE LONDON PARTNERSHIP ENTERS NEW PHASE
May 23, 2011
EISAI TO DONATE $200,000 TO AMERICAN RED CROSS IN RESPONSE TO RECENT TORNADOES IN THE UNITED STATES
May 20, 2011
EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF CALCIUM CHANNEL BLOCKING ANTI-ARRHYTHMIC AGENT VASOLAN® FOR PEDIATRIC PATEINTS IN JAPAN
May 20, 2011
EISAI ONCOLOGY TO PRESENT NEW RESEARCH ON PRODUCT PORTFOLIO, PIPELINE AT ASCO ANNUAL MEETING
May 17, 2011
CORRECTION TO CONSOLIDATED FINANCIAL REPORT FOR FISCAL 2010
May 17, 2011
EISAI'S HALAVEN® RECEIVES APPROVAL FROM SWISSMEDIC FOR USE IN LATE-STAGE METASTATIC BREAST CANCER
May 13, 2011
Proposed Change of Representative Officers
May 13, 2011
Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees
April 25, 2011
FDA ISSUES COMPLETE RESPONSE LETTER FOR ARICEPT® PATCH (DONEPEZIL TRANSDERMAL SYSTEM)
April 22, 2011
Abbott Japan and Eisai Receive Approval to Market the Pancreatic Digestive Enzyme Replacement Drug Lipacreon® (pancrelipase) in Japan
April 22, 2011
HALAVEN® RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF INOPERABLE AND RECURRENT BREAST CANCER
April 8, 2011
EISAI ESTABLISHES SALES SUBSIDIARY IN BRAZIL
April 5, 2011
MORPHOTEK, INC. ACQUIRES TUMOR TARGETING ASSETS FROM TRANSMOLECULAR, INC.
Platform Technology Complements Morphotek's Antibody Targeting Technologies and Therapeutic Antibody Platform
April 4, 2011
EISAI ENTERS INTO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH PRISM BIOLAB CONCERNING CBP/尾-CATENIN INHIBITING COMPOUNDS
March 31, 2011
EISAI APPOINTS FIRST LOCALLY-HIRED PRESIDENT AT ITS CHINESE SUBSIDIARY EISAI CHINA INC.
Aims to Make Further Contributions to Patients in China
March 30, 2011
Eisai and Minophagen Pharmaceutical Conclude Japan License Agreement for Cutaneous T-Cell Lymphoma Treatment Bexarotene
March 24, 2011
LANDMARK RULING COMES INTO EFFECT: TREATMENT NOW AVAILABLE FOR PEOPLE IN ENGLAND AND WALES WITH MILD ALZHEIMER'S AT TIME OF DIAGNOSIS
March 23, 2011
HALAVEN™ (ERIBULIN) RECEIVES EUROPEAN COMMISSION APPROVAL FOR ADVANCED BREAST CANCER
March 14, 2011
EISAI TO OFFER DONATION TO TOHOKU PACIFIC EARTHQUAKE RELIEF FUND
March 11, 2011
EISAI CONCLUDES WORLDWIDE STRATEGIC PARTNERSHIP WITH EPIZYME FOR CANCER THERAPEUTICS TARGETING EZH2 EPIGENETIC ENZYME
March 9, 2011
Eisai and Sanko Junyaku to Launch Cobas h 232 Series, a Point-of-Care Testing System for Use in the Early Diagnosis of Cardiovascular Emergencies
March 4, 2011
U.S. FDA APPROVES ANTI-EPILEPTIC AGENT BANZEL® (RUFINAMIDE) ORAL SUSPENSION, 40MG/ML
Indicated for Adjunctive Treatment of Seizures Associated With Lennox-Gastaut Syndrome in Children 4 Years and Older and Adults
March 3, 2011
THE LANCET PUBLISHES RESULTS FROM PIVOTAL STUDY OF EISAI'S HALAVEN® IN PATIENTS WITH LATE-STAGE METASTATIC BREAST CANCER
Phase Ⅲ Study Demonstrated that HALAVEN® Met its Primary Endpoint of Overall Survival
February 28, 2011
EISAI TO DELAY NHI DRUG PRICE REGISTRATION AND LAUNCH OF NERBLOC®, A BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT
February 23, 2011
EISAI'S ORAL ANTICOAGULANT WARFARIN TABLETS APPROVED FOR PEDIATRIC USE IN JAPAN
February 23, 2011
INTELLECTUAL PROPERTY HIGH COURT OF JAPAN RULES TO MAINTAIN ARICEPT® PATENT TERM EXTENSION IN RELATION TO SEVERE ALZHEIMER'S DEMENTIA
February 22, 2011
Eisai, Sanko Junyaku Commence Co-promotion of DT-Navi, a New Touch-Screen System to Help Physicians with ADAS-Jcog. Testing and Assessment of Cognitive Function Change
February 21, 2011
EISAI TO EXPAND SALES OF CHOCOLA BB SERIES INTO ASIA
CHOCOLA BB® DRINK BIT SCHEDULED FOR LAUNCH IN HONG KONG
February 14, 2011
EISAI CONCLUDES JAPAN LICENSE AGREEMENT FOR NEW ARICEPT® TRANSDERMAL FORMULATION
February 10, 2011
SINGAPORE HSA APPROVES EISAI'S HALAVEN® (ERIBULIN MESYLATE) INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER
February 2, 2011
EISAI RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR INVESTIGATIONAL PROTON PUMP INHIBITOR ACIPHEX® EXTENDED-RELEASE CAPSULES, 50 MG
January 28, 2011
U.S. SUBSIDIARY H3 BIOMEDICINE INC. UNDERTAKES THE DEVELOPMENT OF NEXT-GENERATION CANCER DRUGS
The New Company Is Established to Actively Utilize Cancer Genomic Information and Advanced Drug Discovery Chemistry
January 25, 2011
EISAI TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS IN THE U.S. AND EU FOR PERAMPANEL AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN PATIENTS WITH EPILEPSY
Submissions Planned for First Quarter of Fiscal 2011
January 25, 2011
PHASE Ⅲ STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT
January 25, 2011
NOTICE REGARDING CORPORATE NAME CHANGE OF SUBSIDIARY SANKO JUNYAKU CO., LTD.
January 24, 2011
HALAVEN™ RECEIVES CHMP POSITIVE OPINION FOR USE IN METASTATIC BREAST CANCER
CHMP Opinion Based on Positive EMBRACE Study Data
January 21, 2011
EISAI RECEIVES APPROVAL TO MARKET BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN
January 18, 2011
FINAL NICE APPRAISAL RECOMMENDS IMPROVED ACCESS TO TREATMENT AND CARE OF PEOPLE WITH EARLY ALZHEIMER'S DISEASE
January 17, 2011
EISAI SIGNS PUBLIC-PRIVATE PARTNERSHIP AGREEMENT WITH APOLLO HOSPTIALS AND HELPAGE INDIA TO IMPROVE ACCESS TO MEDCINES IN INDIA
January 17, 2011
EISAI COMMENCES OPERATIONS AT NEW CHINESE PHARMACEUTICAL TRADING SUBSIDIARY
January 7, 2011
EISAI TO LAUNCH NEW ALLERGY MEDICATION SKAINAR® AL TABLETS
Relieves Nasal Congestion, Runny Nose and Various Symptoms Associated With Hay Fever and Other Allergies
